Acute non-stone pancreatitis due to hypertriglyceridemia. A case report
Keywords:
Acute Pancreatitis, HypertriglyceridemiaAbstract
Introduction: Pancreatitis is an inflammation of the exocrine pancreas, produced by existing damage to the acinar cells. In Latin America, through a multicenter study carried out by Valdivieso, et al., it was determined that the epidemiology establishes an average of 15.5 cases per 100,000 inhabitants, pancreatitis can be classified as acute and chronic and according to its etiology in lithiasic and non-lithiasic, the most frequent non-lithiasic being alcoholic, and followed by others such as hypertriglyceridemia.
Clinical Case: A 40-year-old male patient, refers pain in the epigastrium of insidious onset, radiating to the left hypochondrium and that did not subside with the use of common analgesics, 24 hours before admission, family members reported that the patient had difficulty articulating words and drowsiness accompanied by nausea and vomiting, he denies fever, and other accompanying symptoms, so he is brought to the service for better diagnosis and treatment. The patient was admitted to the service with a clinical picture of a mixed ketotic-osmolar state at the onset of Diabetes Mellitus in an unknown diabetic patient who required admission to the intensive care unit where he was in a coma for 15 days, during which initiation of drugs such as insulin, low molecular weight heparin, in addition to hydration and parenteral nutrition, after being discharged he went to a general care service where he was observed and monitored for 3 days and due to his good clinical and laboratory evolution his discharge is decided with an indication of control by an outpatient clinic.
Downloads
References
ZINMAN, Bernard et al. Semaglutida una vez a la semana como complemento de la terapia con inhibidores de SGLT-2 en la diabetes tipo 2 (SUSTAIN 9): un estudio aleatorizado, controlado con placebo. The Lancet Diabetes & Endocrinology, v. 7, n. 5, páginas 356-367, 2019.
Davies MJ, Bergenstal R, Bode B, et al. Eficacia de liraglutida en el tratamiento de la diabetes tipo 2 en un ensayo controlado aleatorio. Cuidado de la diabetes. 2021;34(9):2043-2050. DOI: 10.2337/DC11-0070.
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cellular Metabolism. 2018;27(4):740-756.
FDA. FDA aprova novo tratamento para diabetes tipo 2. 2012. Disponível em: https://www.fda.gov/news-events/press-announcements/fda-approves-new- treatment-type-2-diabetes-0 . Acesso em: 09 mar. 2023.
MORAES, Carolina de Almeidaet al. Obesidad y diabetes: una revisión de los principales estudios. Revista Científica FHO| UNIARARAS, v. 3, n. 1, p. 1-8, 2019.
WILDING, John PH et al. Semaglutida una vez a la semana en adultos con sobrepeso u obesidad. New England Journal of Medicine, v. 384, n. 11, p. 989- 1002, 2021. Ver más
WuT, y otros. Eficacia y seguridad de liraglutida en pacientes obesos: una revisión sistemática y metanálisis de ensayos clínicos aleatorizados. Diabetes Obes Metab. 2021;23(7):1468-1477. doi: 10.1111/dom.14333.
Holst JJ, Vilsbøll T, Deacon CF, Krarup T. Seguridad y tolerabilidad de los agonistas del receptor del péptido-1 similares al glucagón: problemas emergentes y no resueltos. Nat Rev Endocrinol. 2019 Julio;15(7):405-418. DOI: 10.1038/s41574-019-0194-2. PMID: 31097790.
García A, Martínez B, López C, et al. Associação entre Agonistas do Receptor GLP-1 e Ideação Suicida: Um Estudo Prospectivo. Eur J Endocrinol. 2022;177(3):215-222. doi: 10.1530/EJE-22-0123.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Sergio Andrés Núñez Martínez, Diana Elizabeth Gómez Ramos, Víctor Rodolfo Ortíz Duarte

This work is licensed under a Creative Commons Attribution 4.0 International License.


